The Aberdeen Asset Management PLC UK Reduces Position in Boston Scientific Corporation (BSX), Report finds

A number of other hedge funds have also bought and sold shares of the company. First American Trust FSB boosted its stake in Boston Scientific Corporation by 33.3% in the third quarter. First American Trust FSB now owns 134,341 shares of the company’s stock worth $3,197,000 after buying an additional 33,588 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Boston Scientific Corporation by 14.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 613,289 shares of the company’s stock worth $14,596,000 after buying an additional 75,768 shares during the last quarter. Quadrature Capital Ltd acquired a new stake in Boston Scientific Corporation during the third quarter worth about $9,577,000. Synovus Financial Corp acquired a new stake in Boston Scientific Corporation during the third quarter worth about $102,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Boston Scientific Corporation by 16.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 157,099 shares of the company’s stock worth $3,739,000 after buying an additional 21,814 shares during the last quarter. 91.70% of the stock is owned by institutional investors and hedge funds.

Aberdeen Asset Management PLC UK decreased its position in Boston Scientific Corporation (NYSE:BSX) by 5.6% during the fourth quarter, Holdings Channel reports. The fund owned 907,326 shares of the company’s stock after selling 53,733 shares during the period. Aberdeen Asset Management PLC UK’s holdings in Boston Scientific Corporation were worth $19,626,000 at the end of the most recent quarter.

Shares of Boston Scientific Corporation (NYSE:BSX) traded up 0.48% during trading on Monday, reaching $25.32. The company’s stock had a trading volume of 5,054,643 shares. Boston Scientific Corporation has a 12-month low of $16.40 and a 12-month high of $25.45. The company has a market cap of $34.49 billion, a PE ratio of 101.28 and a beta of 1.06. The company has a 50 day moving average of $23.49 and a 200 day moving average of $22.94.

Boston Scientific Corporation (NYSE:BSX) last issued its quarterly earnings results on Thursday, February 2nd. The company reported $0.30 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.29 by $0.01. The firm had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.16 billion. Boston Scientific Corporation had a net margin of 4.14% and a return on equity of 23.70%. Boston Scientific Corporation’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same period last year, the company posted $0.26 EPS. On average, analysts anticipate that Boston Scientific Corporation will post $1.25 EPS for the current fiscal year.

A number of analysts recently issued reports on BSX shares. BTIG Research reissued a “hold” rating on shares of Boston Scientific Corporation in a research note on Sunday, February 5th. TheStreet raised shares of Boston Scientific Corporation from a “c+” rating to a “b” rating in a research note on Tuesday, January 17th. Needham & Company LLC raised their price target on shares of Boston Scientific Corporation from $28.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday, February 2nd. Jefferies Group LLC reaffirmed a “hold” rating and set a $26.00 price target on shares of Boston Scientific Corporation in a research note on Friday, February 3rd. Finally, Vetr raised shares of Boston Scientific Corporation from a “buy” rating to a “strong-buy” rating and set a $23.52 price target for the company in a research note on Monday, December 5th. Six analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $25.88.

In other Boston Scientific Corporation news, EVP Keith D. Dawkins sold 80,783 shares of the firm’s stock in a transaction that occurred on Tuesday, February 7th. The shares were sold at an average price of $25.21, for a total value of $2,036,539.43. Following the transaction, the executive vice president now directly owns 75,864 shares of the company’s stock, valued at approximately $1,912,531.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP David A. Pierce sold 10,232 shares of the firm’s stock in a transaction that occurred on Monday, January 9th. The stock was sold at an average price of $22.24, for a total transaction of $227,559.68. Following the completion of the transaction, the senior vice president now directly owns 25,600 shares in the company, valued at $569,344. The disclosure for this sale can be found here. Insiders sold a total of 123,936 shares of company stock worth $2,949,224 over the last three months. Corporate insiders own 1.31% of the company’s stock.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Leave a Reply

Your email address will not be published. Required fields are marked *